- Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophreniaAngela L Hill
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
BMC Psychiatry 11:28. 2011..2010), apparent dose-associated changes were noted in both efficacy and safety parameters. To help clinicians balance safety and efficacy when choosing a dose of olanzapine LAI, we further studied these changes...
- Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitationRobert W Baker
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
J Clin Psychopharmacol 23:342-8. 2003..Rapid assessment and effective treatment are necessary to manage agitation and, potentially, to shorten the time to recovery...
- Dose response and atypical antipsychotics in schizophreniaBruce J Kinon
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
CNS Drugs 18:597-616. 2004..Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics...
- Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophreniaBruce J Kinon
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Int J Neuropsychopharmacol 6:97-102. 2003..05). Olanzapine orally disintegrating tablets were well-tolerated. Olanzapine orally disintegrating tablets may benefit acutely ill, non-compliant schizophrenic patients by facilitating acceptance of active antipsychotic drug therapy...